<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE">
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<title>Meditrust Healthcare Inc. v. Shoppers Drug Mart, a Division of Imasco Retail 
Inc. (October 18, 2002)</title>
<style><!--
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:553679495 -2147483648 8 0 66047 0;}
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	mso-pagination:widow-orphan;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
h1
	{mso-style-next:Normal;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:15.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-font-kerning:0pt;
	mso-ansi-language:EN-US;
	font-weight:normal;}
h2
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
h3
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	mso-bidi-font-weight:normal;}
h5
	{mso-style-next:Normal;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:5;
	tab-stops:-72.0pt -36.0pt .05pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt 468.0pt 504.0pt 540.0pt 576.0pt 612.0pt 648.0pt 684.0pt 720.0pt 756.0pt 792.0pt 828.0pt 864.0pt 900.0pt 936.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-pagination:widow-orphan;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-pagination:widow-orphan;
	tab-stops:center 216.0pt right 432.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-pagination:widow-orphan;
	tab-stops:center 216.0pt right 432.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoCommentReference
	{mso-ansi-font-size:8.0pt;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-parent:"";
	mso-pagination:widow-orphan;
	tab-stops:24.0pt 48.0pt 72.0pt 96.0pt 120.0pt 144.0pt 168.0pt 192.0pt 216.0pt;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-pagination:widow-orphan;
	background:navy;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.headingtitle, li.headingtitle, div.headingtitle
	{mso-style-name:"heading\: title";
	mso-style-update:auto;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	tab-stops:0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt lined 216.0pt blank 252.0pt 324.0pt 360.0pt 396.0pt 468.0pt 504.0pt 540.0pt 612.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.headingNUMBER, li.headingNUMBER, div.headingNUMBER
	{mso-style-name:"heading\: NUMBER";
	mso-style-update:auto;
	text-indent:0cm;
	mso-pagination:widow-orphan;
	mso-list:l1 level1 lfo18;
	tab-stops:0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt 468.0pt 504.0pt 540.0pt 612.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.headingsubtitle, li.headingsubtitle, div.headingsubtitle
	{mso-style-name:"heading\: subtitle";
	mso-style-update:auto;
	text-indent:-18.0pt;
	mso-pagination:widow-orphan;
	mso-outline-level:4;
	mso-list:l20 level4 lfo17;
	tab-stops:0cm 54.0pt 108.0pt 144.0pt 180.0pt lined 216.0pt blank 252.0pt 324.0pt 360.0pt 396.0pt 468.0pt 504.0pt 540.0pt 612.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.headingsubsubtitle, li.headingsubsubtitle, div.headingsubsubtitle
	{mso-style-name:"heading\: subsubtitle";
	text-indent:0cm;
	mso-pagination:widow-orphan;
	mso-outline-level:5;
	mso-list:l20 level5 lfo17;
	tab-stops:0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt lined 216.0pt blank 252.0pt 324.0pt 360.0pt 396.0pt 468.0pt 504.0pt 540.0pt 612.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.headingQUOTE, li.headingQUOTE, div.headingQUOTE
	{mso-style-name:"heading\: QUOTE";
	text-indent:0cm;
	mso-pagination:widow-orphan;
	mso-list:l20 level3 lfo17;
	tab-stops:0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt lined 216.0pt blank 252.0pt 324.0pt 360.0pt 396.0pt 468.0pt 504.0pt 540.0pt 612.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.headingblank, li.headingblank, div.headingblank
	{mso-style-name:"heading\: blank";
	mso-style-update:auto;
	text-indent:0cm;
	line-height:200%;
	mso-pagination:widow-orphan;
	mso-list:l20 level7 lfo17;
	tab-stops:0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt lined 216.0pt blank 252.0pt 324.0pt 360.0pt 396.0pt 468.0pt 504.0pt 540.0pt 612.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.heading3subtitle, li.heading3subtitle, div.heading3subtitle
	{mso-style-name:"heading\: 3subtitle";
	text-indent:-36.0pt;
	mso-pagination:widow-orphan;
	mso-outline-level:6;
	mso-list:l4 level6 lfo13;
	tab-stops:list 108.0pt;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
@page Section1
	{size:612.0pt 792.0pt;
	mso-header-
	mso-footer-
	mso-page-numbers:1;
	mso-title-page:yes;
	mso-even-header: url(meditrustC36688.htm) eh1;
	mso-header: url(meditrustC36688.htm) h1;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
@list l0
	{mso-list-id:-131;
	mso-list-type:simple;
	mso-list-template-ids:1265521074;}
@list l0:level1
	{mso-level-tab-stop:60.45pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1
	{mso-list-id:234978892;
	mso-list-template-ids:-825340556;}
@list l1:level1
	{mso-level-style-link:"heading\: NUMBER";
	mso-level-text:"\[%1\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;
	mso-ansi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;}
@list l1:level2
	{mso-level-text:"%2\)";
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-32.4pt;
	mso-ansi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;}
@list l1:level3
	{mso-level-number-format:roman-lower;
	mso-level-text:"%3\)";
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-36.0pt;}
@list l1:level4
	{mso-level-number-format:alpha-lower;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-36.0pt;}
@list l1:level5
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l1:level6
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l1:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l1:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l1:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l2
	{mso-list-id:248387907;
	mso-list-template-ids:-853636652;}
@list l2:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l2:level2
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l2:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l2:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l2:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l2:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:36.0pt;}
@list l2:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l2:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l2:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l3
	{mso-list-id:388502664;
	mso-list-type:simple;
	mso-list-template-ids:-1467875128;}
@list l3:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-252.0pt;
	font-family:Symbol;}
@list l4
	{mso-list-id:527061025;
	mso-list-template-ids:-1806136252;}
@list l4:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l4:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l4:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l4:level4
	{mso-level-reset-level:level1;
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l4:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l4:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l4:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l4:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l4:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l5
	{mso-list-id:614597124;
	mso-list-type:simple;
	mso-list-template-ids:436120644;}
@list l5:level1
	{mso-level-start-at:4;
	mso-level-text:"\(%1\)";
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l6
	{mso-list-id:764231896;
	mso-list-template-ids:1352008676;}
@list l6:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l6:level2
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l6:level3
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"%3\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-36.0pt;}
@list l6:level4
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l6:level5
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l6:level6
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l6:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l6:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l6:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l7
	{mso-list-id:911693226;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l7:level1
	{mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l8
	{mso-list-id:945310541;
	mso-list-type:simple;
	mso-list-template-ids:528242088;}
@list l8:level1
	{mso-level-tab-stop:54.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l9
	{mso-list-id:1023559326;
	mso-list-type:simple;
	mso-list-template-ids:-605014332;}
@list l9:level1
	{mso-level-start-at:2;
	mso-level-text:"\(%1\)";
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l10
	{mso-list-id:1240559318;
	mso-list-type:simple;
	mso-list-template-ids:-1116571500;}
@list l10:level1
	{mso-level-start-at:2;
	mso-level-number-format:roman-lower;
	mso-level-text:"\(%1\)";
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-36.0pt;}
@list l11
	{mso-list-id:1250120100;
	mso-list-template-ids:-2020592624;
	mso-list-name:QUOTE;}
@list l11:level1
	{mso-level-number-format:none;
	mso-level-text:"";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l11:level2
	{mso-level-text:"\[%2\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l11:level3
	{mso-level-number-format:none;
	mso-level-text:%3;
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l11:level4
	{mso-level-suffix:none;
	mso-level-text:"\(%4\)\0009";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-36.0pt;}
@list l11:level5
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%5\)\0009";
	mso-level-tab-stop:162.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l11:level6
	{mso-level-number-format:roman-lower;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:126.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level7
	{mso-level-tab-stop:126.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l11:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l12
	{mso-list-id:1299992529;
	mso-list-template-ids:-1740998046;}
@list l12:level1
	{mso-level-text:"\[%1\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l12:level2
	{mso-level-number-format:none;
	mso-level-text:"";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l12:level3
	{mso-level-text:"%1\.%2\.%3\.";
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-25.2pt;}
@list l12:level4
	{mso-level-text:"%1\.%2\.%3\.%4\.";
	mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-32.4pt;}
@list l12:level5
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.";
	mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-39.6pt;}
@list l12:level6
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.";
	mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-46.8pt;}
@list l12:level7
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.";
	mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-54.0pt;}
@list l12:level8
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.";
	mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-61.2pt;}
@list l12:level9
	{mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9\.";
	mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-72.0pt;}
@list l13
	{mso-list-id:1315601249;
	mso-list-type:simple;
	mso-list-template-ids:-52672024;}
@list l13:level1
	{mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l14
	{mso-list-id:1383941449;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l14:level1
	{mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l15
	{mso-list-id:1550385919;
	mso-list-template-ids:821708086;}
@list l15:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l15:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l15:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l15:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l15:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l15:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l15:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l15:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l15:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16
	{mso-list-id:1665664019;
	mso-list-template-ids:-1754337048;}
@list l16:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l16:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l17
	{mso-list-id:1682200304;
	mso-list-template-ids:426402662;}
@list l17:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l17:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l17:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l17:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l17:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l17:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:36.0pt;}
@list l17:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l17:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l17:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l18
	{mso-list-id:1782457026;
	mso-list-type:simple;
	mso-list-template-ids:1131831968;}
@list l18:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l19
	{mso-list-id:1816682448;
	mso-list-template-ids:-784801062;}
@list l19:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l19:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l19:level3
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-text:"%3\)";
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-36.0pt;}
@list l19:level4
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%4\)";
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l19:level5
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l19:level6
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l19:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l19:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l19:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l20
	{mso-list-id:2055880998;
	mso-list-template-ids:1408123706;}
@list l20:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l20:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:-3.6pt;
	mso-ansi-font-size:13.0pt;
	font-family:"Times New Roman";
	mso-ansi-font-weight:normal;
	mso-ansi-font-style:normal;}
@list l20:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-style-link:"heading\: QUOTE";
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l20:level4
	{mso-level-reset-level:level1;
	mso-level-style-link:"heading\: subtitle";
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l20:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-style-link:"heading\: subsubtitle";
	mso-level-suffix:none;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l20:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:36.0pt;}
@list l20:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l20:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l20:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21
	{mso-list-id:2059817004;
	mso-list-template-ids:-1213419456;}
@list l21:level1
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%1;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21:level2
	{mso-level-reset-level:level1;
	mso-level-text:"\[%2\]";
	mso-level-tab-stop:18.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21:level3
	{mso-level-number-format:none;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:%3;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21:level4
	{mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21:level5
	{mso-level-number-format:alpha-lower;
	mso-level-reset-level:level1;
	mso-level-text:"\(%5\)";
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21:level6
	{mso-level-number-format:roman-lower;
	mso-level-reset-level:level1;
	mso-level-suffix:none;
	mso-level-text:"\(%6\)";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21:level7
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:"";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21:level8
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
@list l21:level9
	{mso-level-number-format:none;
	mso-level-suffix:none;
	mso-level-text:%9;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:0cm;}
ol
	{ul
	{-->
</style>
</head>
<body lang=EN-CA style='tab-interval:36.0pt' bgcolor="#FFFFFF">
<div class=Section1> 
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-US>DATE: 
    20021018<br>
    </span><span
lang=EN-US>DOCKET: C36688</span></p>
  <h1><span lang=EN-US>COURT OF APPEAL FOR ONTARIO</span></h1>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US
style='font-size:15.0pt;mso-bidi-font-size:10.0pt'>CARTHY, WEILER and LASKIN JJ.A.</span></p>
  <table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span lang=EN-US>BETWEEN:</span></b></p></td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><span lang=EN-US>MEDITRUST HEALTHCARE INC.</span></p></td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><span lang=EN-US>Ronald D. Manes, David M. Golden and 
          Duncan N. Embury,<br>
          </span><span lang=EN-US>for the appellant</span></p></td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><span lang=EN-US><span
  style='mso-tab-count:2'>                                    </span>Plaintiff</span></p>
        <p class=MsoNormal><span lang=EN-US><span
  style='mso-tab-count:2'>                                    </span>(Appellant)</span></p></td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p>
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><b style='mso-bidi-font-weight:
  normal'><span lang=EN-US>- and -</span></b></p></td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><span lang=EN-US>SHOPPERS DRUG MART, a Division of 
          IMASCO RETAIL INC., SHOPPERS DRUG MART LIMITED, DAVID BLOOM, ARTHUR 
          KONVISER, LAWRENCE ROSEN, THE SOCIETY FOR CONCERNED PHARMACISTS, GLORIA 
          ANDERSON, CAROLINE BEDARD SMITH, THE METROPOLITAN TORONTO PHARMACISTS’ 
          ASSOCIATION, RUTH MALLON, SAM HIRSCH, CANADIAN PHARMACEUTICAL ASSOCIATION, 
          LEROY FEVANG, ONTARIO PHARMACISTS’ ASSOCIATION and CANADIAN ASSOCIATION 
          OF CHAIN DRUG STORES</span></p></td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)<br>
          </span><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><span lang=EN-US>Mark A. Gelowitz,<br>
          </span><span lang=EN-US>for the respondent Shoppers Drug Mart</span></p>
        <p class=MsoNormal><span lang=EN-US>Ed Morgan,<br>
          </span><span lang=EN-US>for the respondent Lawrence Rosen</span></p>
        <p class=MsoNormal><span lang=EN-US>Rochelle Fox,<br>
          </span><span lang=EN-US>for the respondent Sam Hirsch</span></p>
        <p class=MsoNormal><span lang=EN-US>Cheryl M. Woodin, </span></p>
        <p class=MsoNormal><span lang=EN-US>for the respondent Canadian Pharmaceutical 
          Association</span></p></td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><span lang=EN-US><span
  style='mso-tab-count:2'>                                    </span>Defendants<br>
          </span><span lang=EN-US><span
  style='mso-tab-count:2'>                                    </span>(Respondents)</span></p></td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)<br>
          </span><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
    </tr>
    <tr> 
      <td width=313 valign=top style='width:234.9pt;padding:0cm 5.4pt 0cm 5.4pt'>&nbsp;</td>
      <td width=30 valign=top style='width:22.5pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal align=center style='text-align:center'><span lang=EN-US>)</span></p></td>
      <td width=300 valign=top style='width:225.0pt;padding:0cm 5.4pt 0cm 5.4pt'> 
        <p class=MsoNormal><span lang=EN-US>Heard:<span style="mso-spacerun: yes">  
          </span>January 11 and 14, 2002</span></p></td>
    </tr>
  </table>
  <p class=MsoNormal><span lang=EN-US>On appeal from the judgment of Justice Anne 
    Molloy dated July 6, 2001.</span></p>
  <p class=headingtitle><span lang=EN-US>LASKIN J.A.:</span></p>
  <p class=headingtitle><span lang=EN-US>A.&nbsp;&nbsp;INTRODUCTION</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[1]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>This appeal turns on the application of the 
    rule in <i style='mso-bidi-font-style:normal'>Foss v. Harbottle</i> (1843), 
    2 Hare 461, 67 E.R. 189, which holds that a shareholder does not have a cause 
    of action for a wrong done to the corporation.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[2]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The appellant, Meditrust Healthcare Inc., 
    owned a national mail-order pharmacy business, which it operated through a 
    number of subsidiaries.<span style="mso-spacerun: yes">  </span>Meditrust 
    has alleged that Shoppers Drug Mart Limited and the other respondents conspired 
    to destroy its mail-order business.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[3]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The respondents brought a motion for partial 
    summary judgment to dismiss most of Meditrust’s claims.<span
style="mso-spacerun: yes">  </span>The motions judge, Molloy J., granted the motion 
    [at (2001), 15 B.L.R. (3d) 221].<span style="mso-spacerun: yes">  </span>She 
    held that for the claims in question, any damages suffered by Meditrust were 
    not suffered by it directly, but were derivative of damages suffered by the 
    subsidiaries.<span style="mso-spacerun: yes">  </span>In her view, the rule 
    in <i style='mso-bidi-font-style:normal'>Foss v. Harbottle</i> barred these 
    claims.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[4]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust appeals.<span
style="mso-spacerun: yes">  </span>It advances these four submissions:</span></p>
  <p class=headingsubtitle> <span lang=EN-US>1.</span> <span
lang=EN-US><span style='mso-tab-count:1'>   </span>The motions judge failed to 
    apply the proper test for summary judgment under Rule 20.</span></p>
  <p class=headingsubtitle> <span lang=EN-US>2.</span> <span
lang=EN-US><span style='mso-tab-count:1'>   </span>The motions judge erred in 
    holding that Meditrust was not the proper plaintiff.<span style="mso-spacerun:
yes">  </span>Meditrust submits that it is a proper plaintiff for several reasons, 
    including that it suffered personal damages not derivative of the damages 
    to its subsidiaries;</span></p>
  <p class=headingsubtitle> <span lang=EN-US>3.</span> <span
lang=EN-US><span style='mso-tab-count:1'>   </span>The motions judge erred in 
    failing to hold that Meditrust carried on the mail-order pharmacy business;</span></p>
  <p class=headingsubtitle> <span lang=EN-US>4.</span> <span
lang=EN-US><span style='mso-tab-count:1'>   </span>The motions judge erred in 
    refusing to let Meditrust’s conspiracy claim go to trial.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[5]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>For the reasons that follow, I substantially 
    agree with the motions judge.<span style="mso-spacerun: yes">  </span>I would 
    dismiss the appeal except for one claim, Meditrust’s claim for damages for 
    loss of goodwill, which I would let go to trial.</span></p>
  <p class=headingtitle style='page-break-after:avoid'><span lang=EN-US>B.&nbsp;&nbsp;BACKGROUND</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[6]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In 1992, Meditrust began a national mail-order 
    pharmacy business.<span style="mso-spacerun: yes">  </span>Its goal was to 
    provide prescription services at a lower cost than the standard dispensing 
    fees of other retail pharmacies.<span style="mso-spacerun: yes">  </span>To 
    meet provincial legislative and regulatory requirements, Meditrust operated 
    the business through a number of subsidiaries, which it either owned or controlled, 
    and in the province of Quebec through a licensee.<span
style="mso-spacerun: yes">  </span>These subsidiaries and the licensee provided 
    dispensing services and prescription drugs to the public.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[7]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In this action, Meditrust alleges that Shoppers 
    Drug Mart and the other respondents embarked on a global campaign to destroy 
    Meditrust and eliminate it as a competitor in the Canadian retail pharmacy 
    market.<span style="mso-spacerun: yes">  </span>According to the statement 
    of claim, the respondents waged this campaign in several ways, including false 
    advertising and wrongful interference with Meditrust’s suppliers and potential 
    customers.<span style="mso-spacerun: yes">  </span>The most serious complaint, 
    however, is the respondents’ admitted complicity in publishing a phoney letter 
    in October 1996, written on behalf of a fictitious society of pharmacists 
    and alleging that Meditrust’s business was unsafe for patients and investors.<span style="mso-spacerun: yes">  
    </span>The purpose of the letter was to undermine Meditrust’s then ongoing 
    initial public offering (“IPO”).<span style="mso-spacerun: yes">  </span>The 
    IPO failed completely.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[8]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust began this action in 1997.<span style="mso-spacerun: yes">  
    </span>None of the subsidiaries or the Quebec licensee – the operators of 
    the business – is a plaintiff in the action.<span style="mso-spacerun: yes">  
    </span>The lengthy statement of claim alleges that the respondents committed 
    a long list of economic torts that in some way caused economic harm to Meditrust.<span style="mso-spacerun: yes">  
    </span>These torts include conspiracy, intentional interference with contractual 
    relations, intimidation, unfair competition, unlawful infliction of economic 
    harm, misleading advertising and injurious falsehood.<span
style="mso-spacerun: yes">  </span>Because of these alleged torts, Meditrust claims 
    that it sustained damages for loss of revenue, for loss of competitive advantage, 
    and for missed corporate opportunities and other business, and that it suffered 
    damage to its goodwill.<span style="mso-spacerun: yes">  </span></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[9]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In January 1999, nearly two years after it 
    had begun this action, Meditrust sold its mail-order pharmacy business to 
    Pharma Plus Drug Mart.<span style="mso-spacerun: yes">  </span>Meditrust now 
    contends that the main purpose of this litigation is to recover the difference 
    between what it claims the sale price would have been, but for the respondents’ 
    conduct, and the actual sale price to Pharma Plus.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[10]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In June 2001, the respondents moved for partial 
    summary judgment to dismiss most of Meditrust’s claims.<span
style="mso-spacerun: yes">  </span>The respondents acknowledged that Meditrust’s 
    allegations of interference with its IPO (paras. 121-138 of the statement 
    of claim) raised a triable issue, but argued that the remainder of Meditrust’s 
    claims (paras. 1-120 and 139-160 of the statement of claim) disclosed no genuine 
    issue for trial.<span style="mso-spacerun: yes">  </span>Molloy J. agreed.<span style="mso-spacerun: yes">  
    </span>She held that these other claims could be asserted only by the subsidiaries; 
    the companies that operated the mail-order business.<span style="mso-spacerun: yes">  
    </span>She, therefore, granted the partial summary judgment requested by the 
    respondents.</span></p>
  <p class=headingtitle><span lang=EN-US>C.&nbsp;&nbsp;THE LEGAL CONTEXT FOR THE 
    APPEAL</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[11]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The legal context for this appeal has three 
    important aspects:<span style="mso-spacerun: yes">  </span>the rule in <i
style='mso-bidi-font-style:normal'>Foss v. Harbottle</i>; the components of a 
    cause of action for the economic torts alleged by Meditrust, each of which 
    requires proof of damages; and the provincial regulatory scheme, which provides 
    that only a pharmacist or a corporation run by a majority of pharmacists can 
    own or operate a pharmacy.<span style="mso-spacerun: yes">  </span></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[12]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The rule in <i style='mso-bidi-font-style:
normal'>Foss v. Harbottle</i> provides simply that a shareholder of a corporation 
    – even a controlling shareholder or the sole shareholder – does not have a 
    personal cause of action for a wrong done to the corporation.<span
style="mso-spacerun: yes">  </span>The rule respects a basic principle of corporate 
    law:<span style="mso-spacerun: yes">  </span>a corporation has a legal existence 
    separate from that of its shareholders.<span
style="mso-spacerun: yes">  </span>See <i style='mso-bidi-font-style:normal'>Salomon 
    v. Salomon</i>, [1897] A.C. 22, 66 L.J. Ch. 35 (H.L.)<span style="mso-spacerun:
yes">  </span>A shareholder cannot be sued for the liabilities of the corporation 
    and, equally, a shareholder cannot sue for the losses suffered by the corporation.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[13]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The rule in <i style='mso-bidi-font-style:
normal'>Foss v. Harbottle</i> also avoids multiple lawsuits.<span
style="mso-spacerun: yes">  </span>Indeed, without the rule, a shareholder would 
    always be able to sue for harm to the corporation because any harm to the 
    corporation indirectly harms the shareholders.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[14]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <i style='mso-bidi-font-style:normal'><span lang=EN-GB>Foss 
    v. Harbottle</span></i><span lang=EN-GB> was decided nearly 160 years ago 
    but its continuing validity in Canada has recently been affirmed by the Supreme 
    Court of Canada in <i style='mso-bidi-font-style:normal'>Hercules Managements 
    Ltd. v. Ernst &amp; Young</i>, [1997] 2 S.C.R. 165 and by this court in <i
style='mso-bidi-font-style:normal'>Martin v. Goldfarb</i> (1998), 163 D.L.R. (4<sup>th</sup>) 
    639 (C.A.).</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[15]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In <i style='mso-bidi-font-style:normal'>Hercules</i>, 
    La Forest J. described the rule and its rationale in these words at pp.&nbsp;211-12:</span></p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1><span lang=EN-US>The rule in <i
style='mso-bidi-font-style:normal'>Foss v. Harbottle</i> provides that individual 
      shareholders have no cause of action in law for any wrongs done to the corporation 
      and that if an action is to be brought in respect of such losses, it must 
      be brought either by the corporation itself (through management) or by way 
      of a derivative action.<span style="mso-spacerun: yes">  </span>The legal 
      rationale behind the rule was eloquently set out by the English Court of 
      Appeal in <i style='mso-bidi-font-style:normal'>Prudential Assurance Co. 
      v. Newman Industries Ltd. (No. 2)</i>, [1982] 1 All E.R. 354,<span style="mso-spacerun:
yes">  </span>at p. 367, as follows:</span></div>
  </blockquote>
</blockquote>
<div class=Section1></div>
<blockquote> 
  <blockquote> 
    <blockquote> 
      <div class=Section1><span
lang=EN-US style='font-size:12.0pt;mso-bidi-font-size:10.0pt'> The rule [in <i
style='mso-bidi-font-style:normal'>Foss v. Harbottle</i>] is the consequence of 
        the fact that a corporation is a separate legal entity.<span
style="mso-spacerun: yes">  </span>Other consequences are limited liability and 
        limited rights.<span style="mso-spacerun: yes">  </span>The company is 
        liable for its contracts and torts; the shareholder has no such liability.<span
style="mso-spacerun: yes">  </span>The company acquires causes of action for breaches 
        of contract and for torts which damage the company.<span
style="mso-spacerun: yes">  </span>No cause of action vests in the shareholder.<span style="mso-spacerun: yes">  
        </span>When the shareholder acquires a share he accepts the fact that 
        the value of his investment follows the fortunes of the company and that 
        he can only exercise his influence over the fortunes of the company by 
        the exercise of his voting rights in general meeting.<span style="mso-spacerun: yes">  
        </span>The law confers on him the right to ensure that the company observes 
        the limitations of its memorandum of association and the right to ensure 
        that other shareholders observe the rule, imposed on them by the articles 
        of association.<span style="mso-spacerun:
yes">  </span>If it is right that the law has conferred or should in certain restricted 
        circumstances confer further rights on a shareholder the scope and consequences 
        of such further rights require careful consideration.</span></div>
    </blockquote>
    <div class=Section1><span lang=EN-US>To these lucid comments, I would respectfully 
      add that the rule is also sound from a policy perspective, inasmuch as it 
      avoids the procedural hassle of a multiplicity of actions.</span></div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER> <span
lang=EN-GB>[16]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The rule in <i style='mso-bidi-font-style:
normal'>Foss v. Harbottle</i> does not, of course, preclude an individual shareholder 
    from maintaining a claim for harm done directly to it.<span
style="mso-spacerun: yes">  </span>Again, in <i style='mso-bidi-font-style:
normal'>Hercules</i>, La&nbsp;Forest J. explained the limit of the rule at 214:</span></p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1><span lang=EN-US>One final point should be made here.<span style="mso-spacerun: yes">  
      </span>Referring to the case of <i style='mso-bidi-font-style:normal'>Goldex 
      Mines Ltd. v. Revill</i> (1974), 7 O.R. (2d) 216 (C.A.), the appellants 
      submit that where a shareholder has been directly and individually harmed, 
      that shareholder may have a personal cause of action even though the corporation 
      may also have a separate and distinct cause of action.<span style="mso-spacerun: yes">  
      </span>Nothing in the foregoing paragraphs should be understood to detract 
      from this principle.<span
style="mso-spacerun: yes">  </span>In finding that claims in respect of losses 
      stemming from an alleged inability to oversee or supervise management are 
      really derivative and not personal in nature, I have found only that shareholders 
      cannot raise individual claims in respect of a wrong done <u>to the corporation</u>.<span style="mso-spacerun: yes">  
      </span>Indeed, this is the limit of the rule in <i style='mso-bidi-font-style:normal'>Foss 
      v. Harbottle</i>.<span
style="mso-spacerun: yes">  </span>[Emphasis in original.]</span></div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER> <span
lang=EN-GB>[17]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>But he stressed that, to maintain a personal 
    claim, a shareholder must establish all the components of the cause of action 
    alleged:</span></p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1><span lang=EN-US>Where, however, a separate and distinct 
      claim (say, in tort) can be raised with respect to a wrong done to a shareholder 
      <i style='mso-bidi-font-style:normal'>qua</i> individual, a personal action 
      may well lie, assuming that all the requisite elements of a cause of action 
      can be made out.</span></div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER> <span
lang=EN-GB>[18]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In the present case, one of the components 
    of a cause of action for each of the torts alleged by Meditrust is proof of 
    damages suffered.<span style="mso-spacerun: yes">  </span>The tort of conspiracy 
    – the main tort relied on by Meditrust – is typical.<span
style="mso-spacerun: yes">  </span>In <i style='mso-bidi-font-style:normal'>Canada 
    Cement LaFarge Ltd. v. British Columbia Lightweight Aggregate Ltd.</i> (1983), 
    145 D.L.R. (3d) 385 at 398-99, the Supreme Court of Canada affirmed that tort 
    law recognizes a claim of conspiracy where either the predominant purpose 
    of the defendant’s conduct is to injure the plaintiff or where the defendant’s 
    conduct is directed towards the plaintiff, is unlawful and the defendant should 
    know that the plaintiff is, thus, likely to be injured.<span
style="mso-spacerun: yes">  </span>But, in either case, “there must be actual 
    damages suffered by the plaintiff.”<span style="mso-spacerun: yes">  </span>Therefore, 
    Meditrust cannot maintain its action simply by showing that the respondents’ 
    predominant purpose was to harm it or by showing that the respondents engaged 
    in unlawful conduct directed toward it.<span style="mso-spacerun: yes">  </span>Meditrust 
    also has to put forward some evidence that, because of the respondents’ conduct, 
    it suffered damages; damages that are not derivative of the damage suffered 
    by the subsidiaries.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[19]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Yet, because of the prevailing provincial 
    regulatory scheme governing pharmacies, Meditrust could not legally own and 
    operate its national mail-order business.<span style="mso-spacerun:
yes">  </span>To comply with provincial laws, Meditrust had to incorporate subsidiaries 
    to run the business in each province where it wished to locate.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[20]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Ontario was one such province.<span
style="mso-spacerun: yes">  </span>Under s. 142 of Ontario’s <i
style='mso-bidi-font-style:normal'>Drug and Pharmacies Regulation Act</i>, R.S.O. 
    1990, c. H-4, no corporation can own or operate a pharmacy unless the majority 
    of its directors are pharmacists and a majority of each class of its shares 
    is owned by and registered in the name of pharmacists.<span
style="mso-spacerun: yes">  </span>And, under s.&nbsp;144(1) of the Act, “no person 
    other than a pharmacist or a corporation complying with the requirements of 
    s.&nbsp;142 shall own or operate a pharmacy.”<span style="mso-spacerun:
yes">  </span>Only a corporation meeting these statutory requirements could compound 
    and dispense medications – the core function of the mail-order business – 
    and derive revenues from them.<span style="mso-spacerun: yes">  </span>Meditrust 
    did not meet these statutory requirements.<span
style="mso-spacerun: yes">  </span>Thus, it had to incorporate a subsidiary that 
    did.<span style="mso-spacerun: yes">  </span>Indeed, Mr. Paul, the president 
    and chief executive officer of Meditrust, acknowledged in his affidavit that 
    Meditrust operated its mail-order pharmacy business through its subsidiaries 
    and licensees.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[21]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>I turn now to the issues on the appeal.</span></p>
  <p class=headingtitle style='page-break-after:avoid'><span lang=EN-US>D.&nbsp;&nbsp;ANALYSIS</span></p>
  <p class=headingsubtitle style='page-break-after:avoid;mso-list:l8 level1 lfo19;
'> <span
lang=EN-US>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Did the motions judge fail to apply the proper 
    test for summary judgment under Rule 20?</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[22]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust contends that the motions judge 
    did not apply the proper test for summary judgment under Rule 20.<span
style="mso-spacerun: yes">  </span>It advances two submissions:<span
style="mso-spacerun: yes">  </span>the motions judge granted summary judgment 
    even though Meditrust raised questions of mixed fact and law that can only 
    be decided after a trial; and the motions judge wrongly held that Meditrust 
    was required to lead all of the evidence on damages that it might lead at 
    trial.<span
style="mso-spacerun: yes">  </span>I do not agree with these submissions.<span
style="mso-spacerun: yes">  </span>In my view, the motions judge properly applied 
    the Rule&nbsp;20 jurisprudence.<span style="mso-spacerun: yes">  </span></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[23]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>This court and the Supreme Court of Canada 
    have wrestled with different formulations of the summary judgment test under 
    Rule 20.<span style="mso-spacerun: yes">  </span>But two principles have consistently 
    been applied.<span style="mso-spacerun: yes">  </span>First, the moving party 
    has the burden of showing that the claim or defence does not raise a genuine 
    issue for trial.<span style="mso-spacerun: yes">  </span>But, second, because 
    of rule&nbsp;20.04(1), the responding party ordinarily has an evidentiary 
    burden to put forward some evidence in support of its position – it “must 
    lead trump or risk losing.”<span style="mso-spacerun: yes">  </span>In <i
style='mso-bidi-font-style:normal'>High-Tech Group Inc. v. Sears Canada</i> (2001), 
    52 O.R. (3d) 97 (C.A.), after discussing the previous Rule 20 case law, Morden 
    J.A. set out these two principles at 104-105:</span></p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1><span lang=EN-US>These two Ontario decisions, <i style='mso-bidi-font-style:normal'>Dawson</i> 
      more fully than <i style='mso-bidi-font-style:normal'>Irving Ungerman</i>, 
      make it clear that:<span style="mso-spacerun: yes">  </span>(1) the legal 
      or persuasive burden is on the moving party to satisfy the court that there 
      is no genuine issue for trial before summary judgment can be granted (this 
      is what rule 20.04(2) says); and (2), by reason of rule 20.04(1), there 
      is an evidential burden, or something akin to an evidential burden (because 
      the motions judge does not find facts), on the responding party to respond 
      with evidence setting out “specific facts showing that there is a genuine 
      issue for trial”.<span
style="mso-spacerun: yes">  </span>Failure of the responding party to tender evidence 
      does not automatically result in summary judgment.<span
style="mso-spacerun: yes">  </span>The “evidential burden” is described by this 
      court (Catzman, Austin, and Borins JJ.A.) in <i style='mso-bidi-font-style:
normal'>Lang v. Kligerman</i>, [1988] O.J. No. 3708 in paras. 8 and 9 and by the 
      High Court (Griffiths&nbsp;J.) in <i style='mso-bidi-font-style:normal'>Kaighin 
      Capital Inc. v. Canadian National Sportsmen’s Show</i> (1987), 58 O.R. (2d) 
      790 at p. 792, 17 C.P.C. (2d) 59.</span></div>
    <div class=Section1><span lang=EN-US><br>
      The short point is that the motions judge, having considered all of the 
      evidence and the parties’ submissions on it, must be satisfied that there 
      is no genuine issue for trial before he or she may grant summary judgment.<span
style="mso-spacerun: yes">  </span>This is the legal burden resting on the moving 
      party and it never shifts.<span style="mso-spacerun: yes">  </span>I do 
      not think that <i style='mso-bidi-font-style:normal'>Guarantee Co. of North 
      America</i> intended to detract from this.<span style="mso-spacerun: yes">  
      </span>[Footnotes omitted.]</span></div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER> <span
lang=EN-GB>[24]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In granting partial summary judgment, the 
    motions judge applied these two principles and the approach to a Rule 20 motion 
    that underlies them.<span style="mso-spacerun: yes">  </span>Meditrust’s two 
    arguments that she did not do so are misconceived.<span
style="mso-spacerun: yes">  </span>A responding party to a Rule 20 motion does 
    not automatically avoid summary judgment by raising mixed questions of fact 
    and law.<span style="mso-spacerun: yes">  </span>Where the facts are not disputed 
    – as Molloy J. found – a motions judge may, in<span style="mso-spacerun: yes">  
    </span>a proper case, grant summary judgment on these questions.<span
style="mso-spacerun: yes">  </span>See <i style='mso-bidi-font-style:normal'>Guarantee 
    Co. of North America v. Gordon Capital Corp.</i> (1999), 178 D.L.R. (4<sup>th</sup>) 
    1 (S.C.C.);</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[25]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Moreover, Meditrust lost the summary judgment 
    motion not because it failed to lead all of the evidence on damages it might 
    lead at trial, but because, in the view of the motions judge, it led no evidence 
    at all that it had suffered direct damages flowing from the respondents’ conduct.<span style="mso-spacerun: yes">  
    </span>As the motions judge said, though damage was an essential component 
    of the causes of action alleged, “no evidence was filed as to any direct damages 
    sustained by Meditrust.”<span style="mso-spacerun: yes">  </span></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[26]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Accordingly, I would not give effect to this 
    ground of appeal.</span></p>
  <p class=headingsubtitle style='page-break-after:avoid;mso-list:l8 level1 lfo19;
'> <span
lang=EN-US>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Did the motions judge err in holding that 
    Meditrust was not the proper plaintiff?</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[27]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The motions judge’s decision rested on her 
    view that the subsidiaries, not Meditrust, had the right to assert most of 
    the claims advanced in the statement of claim.<span style="mso-spacerun: yes">  
    </span>The subsidiaries, however, are not plaintiffs in the action.<span
style="mso-spacerun: yes">  </span>Meditrust has sold them and, therefore, no 
    longer controls them.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[28]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Still, Meditrust maintains that it is the 
    proper plaintiff.<span style="mso-spacerun: yes">  </span>It puts forward 
    four separate bases on which it claims to have the right to maintain this 
    action:<span style="mso-spacerun: yes">  </span>(1) the business was a single 
    economic entity; (2) principal and agent; (3) it had a contractual right to 
    sue; and (4) it suffered damages personally.<span style="mso-spacerun: yes">  
    </span>I will discuss each of these.</span></p>
  <p class=headingsubsubtitle style='page-break-after:avoid;mso-list:none;
'><span
lang=EN-US>(1)<span style='mso-tab-count:1'> </span><i style='mso-bidi-font-style:
normal'>Single economic entity</i></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[29]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust submits that, because it was at 
    the apex of a single economic entity, the rule in <i style='mso-bidi-font-style:
normal'>Foss v. Harbottle</i> does not preclude it from maintaining this action.<span style="mso-spacerun: yes">  
    </span>Meditrust points out that it completely controlled the subsidiaries, 
    that its control of them was augmented by the unanimous shareholders’ agreement, 
    and was reflected in the consolidated financial statements for the business.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[30]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>This submission shows the difference between 
    economic reality and legal reality.<span style="mso-spacerun: yes">  </span>The 
    economic reality of the mail-order business was a single economic enterprise.<span style="mso-spacerun: yes">  
    </span>But the legal reality was separate corporate entities.<span style="mso-spacerun: yes">  
    </span>And the rule in <i style='mso-bidi-font-style:normal'>Foss v. Harbottle</i> 
    is a corporate law rule, not an economic rule.<span style="mso-spacerun: yes">  
    </span>A parent company that owns all the shares of its subsidiaries may exercise 
    complete and constant control over them.<span style="mso-spacerun:
yes">  </span>That control, however, does not clothe the parent with the right 
    to sue for the subsidiaries.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[31]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In rare cases, a court may disregard separate 
    corporate entities for the benefit of innocent third parties.<span
style="mso-spacerun: yes">  </span>The court may “pierce the corporate veil” when 
    the corporate structure has been used by the corporation’s principals as a 
    sham or to perpetrate a fraud.<span style="mso-spacerun: yes">  </span>See, 
    for example, <i style='mso-bidi-font-style:normal'>642947 Ontario Ltd. v. 
    Fleischer</i> (2001), 56 O.R. (3d) 417 (C.A.).<span style="mso-spacerun: yes">  
    </span>But here, Meditrust must be held to the corporate structure that it 
    created.<span
style="mso-spacerun: yes">  </span>It created a structure in which it operated 
    the business through subsidiaries.<span style="mso-spacerun: yes">  </span>It 
    must take not only the benefits of that structure, but also the burdens.<span
style="mso-spacerun: yes">  </span>The motions judge, thus, properly characterized 
    Meditrust’s attempted disregard of this structure as an attempt “to pierce 
    its own corporate veil.”<span style="mso-spacerun: yes">  </span>Like her, 
    I see no merit in Meditrust’s single economic entity argument.</span></p>
  <p class=headingsubsubtitle style='
mso-list:l9 level1 lfo21;'> <span
lang=EN-US>(2)<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span> 
    <i
style='mso-bidi-font-style:normal'><span lang=EN-US>Principal and agent</span></i></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[32]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust also argues that the relationship 
    between it and its subsidiaries was that of principal and agent.<span style="mso-spacerun: yes">  
    </span>Where an agent enters into a contract on behalf of a principal, the 
    principal can sue for its breach.<span
style="mso-spacerun: yes">  </span>Meditrust seeks to apply this proposition to 
    tort.<span style="mso-spacerun: yes">  </span>It submits that it can sue for 
    the torts committed by the respondents against the subsidiaries.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[33]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The law of principal and agent is concerned 
    with contract and property, not with torts.<span style="mso-spacerun:
yes">  </span>Meditrust cites no authority for the proposition that a principal 
    has the right to sue in tort for harm done to its agent.<span
style="mso-spacerun: yes">  </span>Moreover, Meditrust’s claim of a principal 
    and agent relationship with its subsidiaries seems nothing more than an artificial 
    attempt to avoid summary judgment.<span style="mso-spacerun: yes">  </span>Its 
    statement of claim contains no allegation that it is claiming as principal 
    the damages suffered by its agents.<span style="mso-spacerun: yes">  </span>I 
    would not give effect to this argument.</span></p>
  <p class=headingsubsubtitle style='mso-list:none;'><span
lang=EN-US>(3)<span style='mso-tab-count:1'>  </span><i style='mso-bidi-font-style:
normal'>Contractual right to sue</i></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[34]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust also submits that its security agreements 
    with the subsidiaries enable it to maintain this action.<span style="mso-spacerun: yes">  
    </span>I do not accept this submission either.<span style="mso-spacerun: yes">  
    </span>Again, Meditrust has not pleaded reliance on these agreements in its 
    statement of claim.<span
style="mso-spacerun: yes">  </span>Moreover, these agreements are simply standard 
    form secured-lending agreements, under which Meditrust, as secured lender, 
    has priority over subsequent secured creditors and all unsecured creditors 
    in the case of default by the subsidiaries.<span style="mso-spacerun: yes">  
    </span>No default, however, was alleged.</span></p>
  <p class=headingsubsubtitle style='
mso-list:l5 level1 lfo22;'> <span
lang=EN-US>(4)<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <i style='mso-bidi-font-style:normal'><span lang=EN-US>Personal 
    damages</span></i></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[35]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust’s main argument on appeal – as it 
    was on the motion – is that it put forward enough evidence to raise a triable 
    issue whether it had suffered damages independent from and not derivative 
    of the damages suffered by the subsidiaries.<span
style="mso-spacerun: yes">  </span>The motions judge rejected this argument.<span style="mso-spacerun: yes">  
    </span>She concluded that all the losses claimed by Meditrust were simply 
    derivative of the losses allegedly suffered by the subsidiaries.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[36]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In submitting that the motions judge erred 
    in her conclusion, Meditrust listed four categories of losses, each of which 
    it asserted were direct and not derivative losses.<span
style="mso-spacerun: yes">  </span>These are the four categories:</span></p>
  <p class=MsoNormal><span lang=EN-US><span style='mso-tab-count:1'>            
    </span>&nbsp;&nbsp;(i)&nbsp;&nbsp;loss of business opportunities and contractual 
    relations;</span></p>
  <p class=MsoNormal><span lang=EN-US><span style='mso-tab-count:1'>            
    </span>&nbsp;(ii)&nbsp;&nbsp;the costs of investments in its subsidiaries;</span></p>
  <p class=MsoNormal><span lang=EN-US><span style='mso-tab-count:1'>            
    </span>(iii)&nbsp;&nbsp;loss in the value of its shares in its subsidiaries; 
    and</span></p>
  <p class=MsoNormal><span lang=EN-US><span style='mso-tab-count:1'>            
    </span>(iv)&nbsp;&nbsp;loss of goodwill. </span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[37]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>For each category of loss, Meditrust alleged 
    in its statement of claim and in the affidavit of Mr. Paul that it had “sustained 
    damages.”<span style="mso-spacerun: yes">  </span>This incantation, no matter 
    how often asserted, will not, standing alone, stave off a motion for summary 
    judgment.<span style="mso-spacerun: yes">  </span>A party responding to a 
    motion for summary judgment must do more.<span style="mso-spacerun: yes">  
    </span>As the Supreme Court of Canada said in <i style='mso-bidi-font-style:
normal'>Guarantee Co. of North America v. Gordon Capital Corp.</i>, <i
style='mso-bidi-font-style:normal'>supra</i> at p. 12, “a self-serving affidavit 
    is not sufficient in itself to create a triable issue in the absence of detailed 
    facts and supporting evidence.”</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[38]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In my opinion, Meditrust has not filed any 
    evidence showing it may personally have suffered losses in any of the first 
    three categories it relies on, but it has done so in the fourth category, 
    loss of goodwill.</span></p>
  <p class=MsoNormal style='page-break-after:avoid;'><span
lang=EN-US><span style='mso-tab-count:1'>                              </span>&nbsp;&nbsp;(i)&nbsp;&nbsp;<u>Loss 
    of business opportunities and contractual relations</u></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[39]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust led evidence that it directly entered 
    into a number of contracts and other business arrangements for the supply 
    of prescription drugs.<span style="mso-spacerun: yes">  </span>It contends 
    that the respondents’ tortious acts interfered with these contracts and other 
    arrangements, and thus directly harmed Meditrust.<span
style="mso-spacerun: yes">  </span>For example, Meditrust points to its contract 
    with Sears, which it says was cancelled because of the respondents’ ruinous 
    campaign.<span style="mso-spacerun: yes">  </span>However, these lost contractual 
    or business opportunities were, in reality, lost opportunities for the subsidiaries, 
    not Meditrust.<span style="mso-spacerun: yes">  </span>Only the subsidiaries 
    could operate the mail-order business.<span style="mso-spacerun:
yes">  </span>They alone could benefit from the business arrangements.<span
style="mso-spacerun: yes">  </span>Therefore, they alone would be harmed by their 
    cancellation.<span style="mso-spacerun: yes">  </span>In his affidavit, Mr. 
    Paul gave no evidence to show that Meditrust had suffered damages in its own 
    right because of lost business opportunities.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[40]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The motions judge put it this way in her reasons 
    at 233:</span></p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1><span lang=EN-US>… Meditrust has not filed any evidence 
      of separate damages to it as a result of the failure of any of these contracts 
      or arrangements.<span style="mso-spacerun: yes">  </span>The same reasoning 
      applies to cooperative arrangements with other organizations to advertise 
      Meditrust’s services.<span style="mso-spacerun:
yes">  </span>Meditrust has filed no evidence that it would earn any revenue directly 
      from such business.<span style="mso-spacerun: yes">  </span>It has merely 
      alleged that the mail order business was harmed.<span
style="mso-spacerun: yes">  </span>It relies on the loss of the business itself 
      which, as I have already said, is a loss sustained by the subsidiaries.</span></div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=MsoNormal><span lang=EN-US>I agree with this passage.</span></p>
  <p class=MsoNormal style='page-break-after:avoid;'><span
lang=EN-US><span style='mso-tab-count:1'>                              </span>&nbsp;(ii)&nbsp;&nbsp;<u>The 
    costs of investments in its subsidiaries</u></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[41]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust submits that it suffered losses 
    from its investment in its subsidiaries.<span style="mso-spacerun:
yes">  </span>Yet, it did not even claim these losses in its statement of claim.<span style="mso-spacerun: yes">  
    </span>And it led no evidence that any of its subsidiaries had defaulted on 
    their loans or that it had lost any money as a creditor.</span></p>
  <p class=MsoNormal><span lang=EN-US><span
style='mso-tab-count:1'>                              </span>(iii)&nbsp;&nbsp;<u>Loss 
    in the value of its shares in its subsidiaries</u></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[42]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust also claims that the loss in the 
    value of its shares in its subsidiaries is a direct loss for which it can 
    sue the respondents.<span style="mso-spacerun: yes">  </span>This claim, however, 
    runs up against the rule in <i style='mso-bidi-font-style:normal'>Foss v. 
    Harbottle</i> and was expressly rejected by this court in <i
style='mso-bidi-font-style:normal'>Martin v. Goldfarb</i>, where Finlayson J.A. 
    wrote at 660:</span></p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1><span lang=EN-US>Martin’s claim was premised on the loss 
      he suffered as an equity holder in his various corporations because the 
      conduct of Axton ruined the corporations and destroyed the value of his 
      equity in the corporations.<span style="mso-spacerun: yes">  </span>There 
      is authority of long standing for the proposition that where a wrong is 
      occasioned to a corporation, a shareholder has no claim for damages in respect 
      of that wrong:<span style="mso-spacerun: yes">  </span>see <i
style='mso-bidi-font-style:normal'>Foss v. Harbottle</i> (1843), 2 Hare 461, 67 
      E.R. 189.</span></div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=MsoNormal><span lang=EN-US>See also <i style='mso-bidi-font-style:
normal'>Rogers v. Bank of Montreal</i>, [1985] 5 W.W.R. 193 (B.C.S.C.); aff’d 
    [1987] 2 W.W.R. 364 (B.C.C.A.).<span style="mso-spacerun: yes">  </span>In 
    other words, a shareholder in a company has no independent right of action 
    based on an allegation of diminution in the value of its shares caused by 
    damage to the company.<span style="mso-spacerun: yes">  </span>The shareholder 
    does not suffer a direct loss.<span style="mso-spacerun: yes">  </span>Its 
    loss merely reflects the loss suffered by the company.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[43]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust, nonetheless, submits that this 
    principle, which was affirmed in <i style='mso-bidi-font-style:normal'>Martin 
    v. Goldfarb</i>, should be reconsidered in the light of recent English case 
    law.<span style="mso-spacerun: yes">  </span>I think that submission is untenable 
    for two reasons.<span style="mso-spacerun: yes">  </span>First, Canadian appellate 
    jurisprudence has consistently invoked <i style='mso-bidi-font-style:
normal'>Foss v. Harbottle</i> to reject this kind of claim.<span
style="mso-spacerun: yes">  </span>Second, the most recent English authority, 
    the House of Lords’ decision in <i style='mso-bidi-font-style:normal'>Johnson 
    v. Gore Wood &amp; Co.</i>, [2001] 1 All E.R. 481, does not support Meditrust’s 
    position.<span style="mso-spacerun: yes">  </span>In <i style='mso-bidi-font-style:
normal'>Johnson</i>, Lord Bingham admittedly put a gloss on the rule in <i
style='mso-bidi-font-style:normal'>Foss v. Harbottle</i> when he stated the following 
    proposition at 503:<span style="mso-spacerun: yes">  </span>“Where a company 
    suffers loss but has no cause of action to sue to recover that loss, the shareholder 
    of the company may sue in respect of it (if the shareholder has a cause of 
    action to do so), even though the loss is a diminution in the value of the 
    shareholding.”<span style="mso-spacerun: yes">  </span>But, to rely on this 
    proposition to claim the loss in the value of its shares, Meditrust must at 
    least show that it has a cause of action and the subsidiaries do not.<span
style="mso-spacerun: yes">  </span>This, Meditrust has failed to do.<span
style="mso-spacerun: yes">  </span>Therefore, in my view, Meditrust cannot maintain 
    its claim for damages resulting from the loss in the value of its shares in 
    its subsidiaries.</span></p>
  <p class=MsoNormal style='page-break-after:avoid;'><span
lang=EN-US><span style='mso-tab-count:1'>                              </span>(iv)&nbsp;&nbsp;<u>Loss 
    of goodwill</u></span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[44]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Finally, Meditrust submits that it has a personal 
    claim for damages for loss of goodwill.<span style="mso-spacerun:
yes">  </span>This is the most persuasive of all Meditrust’s submissions.<span
style="mso-spacerun: yes">  </span>In principle, a claim for loss of goodwill 
    is not precluded by the rule in <i style='mso-bidi-font-style:normal'>Foss 
    v. Harbottle</i>.<span style="mso-spacerun: yes">  </span>A shareholder may 
    suffer personal damages for loss of goodwill, damages that are not derivative 
    of harm to the company.<span style="mso-spacerun: yes">  </span>The contentious 
    question on this appeal is whether the evidentiary record supports Meditrust’s 
    claim.<span style="mso-spacerun: yes">  </span>Although Meditrust’s evidence 
    could be stronger, I would permit its claim for harm to its goodwill to go 
    to trial.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[45]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Goodwill includes reputation, position in 
    the business community, client base, the expectation of continued public patronage 
    and like considerations.<span style="mso-spacerun: yes">  </span>See <i
style='mso-bidi-font-style:normal'>DiFlorio v. Con. Structural Steel Ltd.</i>, 
    [2000] O.J. No. 340 (S.C.J.).<span style="mso-spacerun: yes">  </span>It is 
    akin to the loss of reputation claim asserted by the shareholder in <i
style='mso-bidi-font-style:normal'>Martin v. Goldfarb</i>, which this court held 
    could give rise to damages that were direct and not derivative of the damages 
    to the company.<span style="mso-spacerun: yes">  </span>As Finlayson J.A. 
    said, at 672:</span></p>
</div>
<blockquote> 
  <blockquote> 
    <div class=Section1><span lang=EN-US>I also think that Martin is entitled 
      to something for “the insult”, as they say in settlement discussions.<span style="mso-spacerun: yes">  
      </span>He did maintain a certain standard of living before the bankruptcy 
      and he works now as a security guard at a motel in Florida.<span style="mso-spacerun: yes">  
      </span>It may well be that the judge on the assessment would want to consider, 
      if the evidence warrants it, general damages for loss of reputation and 
      credit arising out of the bankruptcy itself:<span style="mso-spacerun: yes">  
      </span>see <i style='mso-bidi-font-style:normal'>Hoskins v. Price Waterhouse 
      Ltd.</i>, <i style='mso-bidi-font-style:normal'>supra</i>.</span></div>
  </blockquote>
</blockquote>
<div class=Section1> 
  <p class=headingNUMBER> <span
lang=EN-GB>[46]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>The respondents, however, mount a formidable 
    array of arguments that, though Meditrust may in principle have a claim for 
    loss of goodwill, it has not provided any evidence to support it.<span style="mso-spacerun: yes">  
    </span>The respondents point out that, though a claim for loss of goodwill 
    was pleaded in the statement of claim, it was not argued before the motions 
    judge.<span style="mso-spacerun: yes">  </span>They also point out that the 
    record contains only brief reference to Meditrust’s goodwill, even though 
    Meditrust had been ordered to particularize the damages it allegedly suffered. 
    </span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[47]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>These are strong arguments.<span
style="mso-spacerun: yes">  </span>But there are balancing considerations.<span
style="mso-spacerun: yes">  </span>The record does show that Meditrust was known 
    publicly as the corporate face of the mail-order business it owned.<span
style="mso-spacerun: yes">  </span>That public reputation is reflected in the 
    following paragraph of Meditrust’s prospectus:</span></p>
</div>
<blockquote> 
  <blockquote>
    <div class=Section1><span lang=EN-US>Management believes that Meditrust will 
      be able to continue to compete effectively in Canada on the basis of its 
      ability to provide national drug containment services, the Company’s experience 
      and the reputation of its mail order pharmacy, its current customer base, 
      its sophisticated pharmacy technology systems and procedures, and the dependable 
      and cost effective manner in which it serves it customers.</span></div>
  </blockquote>
</blockquote>
<div class=Section1>
  <p class=headingNUMBER> <span
lang=EN-GB>[48]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Damage to that reputation would be damage 
    to Meditrust personally, not to its subsidiaries.<span
style="mso-spacerun: yes">  </span>Although Meditrust did not particularize any 
    damage to its reputation, it did put forward cogent evidence that the respondents 
    embarked on a campaign to destroy it and its national mail-order business.<span style="mso-spacerun: yes">  
    </span>It seems to me almost axiomatic that Meditrust would suffer a loss 
    of goodwill from the respondents’ alleged wrongful acts.<span style="mso-spacerun: yes">  
    </span>Although I consider it a close decision, I would err on the side of 
    permitting the claim for damages for loss of goodwill to go to trial.</span></p>
  <p class=headingsubtitle style='mso-list:l8 level1 lfo19;'> <span
lang=EN-US>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Did the motions judge err in failing to hold 
    that Meditrust carried on the mail-order pharmacy business?</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[49]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust submits that the motions judge erred 
    in concluding that the subsidiaries alone carried on the mail-order pharmacy 
    business.<span style="mso-spacerun: yes">  </span>Meditrust submits that it 
    did so as well.<span style="mso-spacerun: yes">  </span>It contends that the 
    motions judge erred because she focused on the dispensing and selling of prescription 
    drugs, which was done by the subsidiaries.<span
style="mso-spacerun: yes">  </span>Meditrust asserts that the business was broader 
    than merely filling prescriptions and embraced the organization and operation 
    of an economic enterprise, including marketing, contracting, advertising, 
    banking and purchasing.<span style="mso-spacerun: yes">  </span>Meditrust 
    says that it carried on these broader aspects of the business.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[50]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Even accepting that Meditrust did so, this 
    ground of appeal must fail for the same reason that Meditrust’s second ground 
    of appeal largely failed.<span style="mso-spacerun: yes">  </span>It put forward 
    no evidence that it suffered losses from the respondents’ interference with 
    these broader aspects of the business.<span style="mso-spacerun: yes">  </span>Instead, 
    Meditrust claimed damages only for lost revenues from the dispensing and selling 
    of drugs.<span style="mso-spacerun: yes">  </span>But only the subsidiaries 
    (and the licensee) carried on these activities.<span
style="mso-spacerun: yes">  </span>Thus, the only damages for loss of income that 
    Meditrust claimed to have suffered and on which it led evidence were damages 
    it suffered as a shareholder.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[51]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In substance, Meditrust did not carry on the 
    mail-order business.<span style="mso-spacerun: yes">  </span>Rather, it owned 
    a group of companies that did.<span style="mso-spacerun: yes">  </span>Mr. 
    Paul acknowledged as much in his affidavit when he discussed potential liabilities 
    for the incorrect preparation, labelling and distribution of prescriptions.<span style="mso-spacerun: yes">  
    </span>He said that these liabilities “based upon the structure of the business, 
    are actually liabilities of the pharmacy subsidiaries filling the individual 
    prescriptions.”<span
style="mso-spacerun: yes">  </span>Meditrust cannot have it both ways.<span
style="mso-spacerun: yes">  </span>It cannot claim to sue for harm in reality 
    caused to the subsidiaries, yet shelter behind these same subsidiaries for 
    any harm done by them.<span style="mso-spacerun: yes">  </span>I would not 
    give effect to this ground of appeal.</span></p>
  <p class=headingsubtitle style='mso-list:l8 level1 lfo19;'> <span
lang=EN-US>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-US>Did the motions judge err in refusing to let 
    the conspiracy claim go to trial?</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[52]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>Meditrust submits on appeal, as it did before 
    the motions judge, that the rule in <i style='mso-bidi-font-style:normal'>Foss 
    v. Harbottle</i> does not apply to a conspiracy claim.<span
style="mso-spacerun: yes">  </span>In other words, Meditrust says it can avoid 
    the rule by showing that the respondents’ unlawful conduct was directed at 
    it.<span style="mso-spacerun: yes">  </span>The motions judge rejected this 
    submission and so do I.</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[53]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>In granting summary judgment on the conspiracy 
    claim, the motions judge held at p. 229 that “the mere fact that Meditrust 
    may have been the direct target of the alleged conspiracy is not sufficient 
    to create a cause of action.<span style="mso-spacerun: yes">  </span>Meditrust 
    must have sustained direct injury in its own right (not as a result of injury 
    to its subsidiaries) before it can have a cause of action.”</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[54]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>I agree.<span style="mso-spacerun:
yes">  </span>I add that Meditrust’s submission runs counter to principle, to 
    the Supreme Court of Canada’s decision in <i style='mso-bidi-font-style:normal'>Canada 
    Cement LaFarge </i>and to this court’s decision in <i style='mso-bidi-font-style:
normal'>Walters v. Royal Bank</i> (2000), 130 O.A.C. 188 (C.A.); [2000] O.J. No. 
    702.<span style="mso-spacerun: yes">  </span>I&nbsp;see no principled basis 
    for holding that the rule in <i style='mso-bidi-font-style:normal'>Foss v. 
    Harbottle</i> applies to other tort claims but not to a conspiracy claim.<span
style="mso-spacerun: yes">  </span>Moreover, <i style='mso-bidi-font-style:
normal'>Canada Cement LaFarge</i>, to which I referred earlier, states unequivocally 
    that a plaintiff who alleges conspiracy must suffer direct injury in its own 
    right before it can sue.<span style="mso-spacerun: yes">  </span>And in <i style='mso-bidi-font-style:normal'>Walters</i>, 
    this court approved the decision of the British Columbia Court of Appeal in 
    <i style='mso-bidi-font-style:
normal'>Rogers v. Bank of Montreal</i>, which, in turn, affirmed the proposition 
    that an allegation of conspiracy does not affect the application of the rule 
    in <i style='mso-bidi-font-style:normal'>Foss v. Harbottle</i>.<span
style="mso-spacerun: yes">  </span>For these reasons, I would not give effect 
    to this ground of appeal.</span></p>
  <p class=headingtitle><span lang=EN-US>E.<span style="mso-spacerun: yes">  </span>DISPOSITION</span></p>
  <p class=headingNUMBER> <span
lang=EN-GB>[55]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
    </span></span> <span lang=EN-GB>I would allow the appeal only on the claim 
    for damages for loss of goodwill.<span style="mso-spacerun: yes">  </span>To 
    that extent, I would set aside the order of the motions judge and dismiss 
    the motion for summary judgment.<span style="mso-spacerun: yes">  </span>I 
    would otherwise dismiss the appeal.<span style="mso-spacerun: yes">  </span>The 
    parties may make written submissions on the costs of the appeal – both entitlement 
    and amount – within 30 days of the release of the court’s judgment.</span></p>
  <p class=MsoNormal><span lang=EN-US>Released: OCT 18 2002<br>
    <span
style='mso-tab-count:3'>                      </span><span lang=EN-US>JJC<span style='mso-tab-count:7'>  </span></span><span
style='mso-tab-count:3'>       </span></span></p>
  <p class=MsoNormal align="right"><span lang=EN-US>Signed: “John Laskin J.A.” 
    </span></p>
  <p class=MsoNormal align="right"><span lang=EN-US><span style='mso-tab-count:7'>                                                                            
    </span><span
style="mso-spacerun: yes">  </span>“I agree<span style="mso-spacerun: yes">  </span>J.J. 
    Carthy J.A.”</span></p>
  <p class=MsoNormal align="right"><span lang=EN-US><span style='mso-tab-count:7'>                                                                                    
    </span><span
style="mso-spacerun: yes">  </span>“I agree<span style="mso-spacerun: yes">  </span>K.M. 
    Weiler J.A.”</span></p>
</div>
</body>
</html>
